ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review.
Allergic diseases constitute a global health problem, as they have an increasing economic and social impact and, especially, they can deeply interfere with the patients' daily life, being a cause of physical and emotional discomfort. This is why the health-related quality-of-life (HRQoL) has become increasingly important in health care research; in fact, the assessment of the impact the disease and its treatment have on patients, provides a more comprehensive approach in outcome evaluation. Numerous validated questionnaires are available and many studies have been performed evaluating HRQoL in people affected by allergic rhinitis (AR), thus testifying a great interest in this topic. The aims of the present review are: to examine the scientific literature of the last 3 years dealing with the impact of AR treatments suggested by allergic rhinitis and its impact on asthma guidelines on patients' QoL, and to identify the unexplored or not-fully-investigated areas concerning this issue.
Baiardini
I
I
Allergy & Respiratory Diseases, DIMI - University of Genoa, Genoa, Italy.
Braido
F
F
Tarantini
F
F
Porcu
A
A
Bonini
S
S
Bousquet
P-J
PJ
Zuberbier
T
T
Demoly
P
P
Canonica
G W
GW
D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017281:Cost of Illness; D003888:Desensitization, Immunologic; D004333:Drug Administration Routes; D006302:Health Services Research; D006801:Humans; D007167:Immunotherapy; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D011795:Surveys and Questionnaires
D018926:Anti-Allergic Agents